TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522431-34-00

Enrollment

1200

Registered

2026-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Brief summary

Progression-free survival

Detailed description

Overall Survival (OS) and OS rate at 6 and 12 months, Objective Response Rate and Disease Control Rate, Duration of Response, Progression-free survival on subsequent treatment (PFS 2), Adverse events with causal relationship to study treatment, Adjusted mean change from baseline in global health status/QoL score, and functional and symptom scales from the EORTC QLQ-C30 questionnaire.

Interventions

DRUGOLAPARIB

DRUGERLOTINIB

DRUGCRIZOTINIB

DRUGOXALIPLATIN

DRUGTRAMETINIB

DRUGPEMIGATINIB

DRUGSELPERCATINIB

DRUGAXITINIB

DRUGVISMODEGIB

DRUGCAPECITABINE

DRUGPEMBROLIZUMAB

DRUGIRINOTECAN

DRUGLAROTRECTINIB

DRUGDABRAFENIB

DRUGFLUOROURACIL

DRUGPhesgo 1200 mg/600 mg solution for injection

DRUGCALCIUM FOLINATE

DRUGPhesgo 600 mg/600 mg solution for injection

DRUGGEMCITABINE

DRUGPACLITAXEL ALBUMIN-BOUND

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall Survival (OS) and OS rate at 6 and 12 months, Objective Response Rate and Disease Control Rate, Duration of Response, Progression-free survival on subsequent treatment (PFS 2), Adverse events with causal relationship to study treatment, Adjusted mean change from baseline in global health status/QoL score, and functional and symptom scales from the EORTC QLQ-C30 questionnaire.	—

Outcome results

None listed

Source: EU CTIS · Data processed: May 19, 2026